Poolbeg Pharma plc
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Effects of p38 MAPK Inhibitor POLB 001 on in Vivo LPS Challenge Responses (NCT05765955) | Poolbeg Pharma plc | 2022-07-22 |
Track Poolbeg Pharma plc automatically
Every clearance here is in the API, with alerts when new ones post.